Clopidogrel Tablet
Product Images NDC 65162-414

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 65162-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

11393254-figure-01 (Clopidogrel Tablets Usp 1)

Chemical structure of clopidogrel, showing its molecular components including a thiophene ring, a chlorophenyl group, and a methyl ester functional group, associated with sulfuric acid (H2SO4).*

FDA Label Image

11393254-figure-10 (Clopidogrel Tablets Usp 10)

A forest plot chart comparing Clopidogrel and Aspirin across qualifying conditions including Stroke, MI, and PAD. The chart shows the hazard ratio (95% CI) favoring either Clopidogrel or Aspirin, with numerical data of event counts and percentages for each treatment group. The overall comparison includes data from 19,185 subjects, providing a visual summary of relative risk between the two drugs.*

FDA Label Image

Clopidogrel Label (Clopidogrel Tablets Usp 11)

Clopidogrel Tablets, USP 75 mg oral tablets by Amneal Pharmaceuticals LLC. The label includes a picture of a pink round tablet marked "A9" and indicates a package of 30 tablets. The label shows NDC 65162-414-03, states Rx only, and provides storage and dosage instructions along with manufacturer and distributor information. A QR code and barcode are also visible.*

FDA Label Image

11393254-figure-02 (Clopidogrel Tablets Usp 2)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPI) on the active metabolite AUC of Clopidogrel. It presents mean values and 90% confidence intervals for four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with changes relative to Clopidogrel administered alone on the x-axis.*

FDA Label Image

11393254-figure-03 (Clopidogrel Tablets Usp 3)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two curves compare placebo (+ aspirin) versus clopidogrel (+ aspirin) treatment groups, with the clopidogrel group exhibiting a lower cumulative event rate throughout the period. A statistical significance value (P=0.00009) is noted on the graph.*

FDA Label Image

11393254-figure-04 (Clopidogrel Tablets Usp 4)

A forest plot depicting the hazard ratio (with 95% confidence intervals) for various subgroups comparing Clopidogrel to placebo. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The plot shows the relative risk favoring either Clopidogrel or placebo across these groups.*

FDA Label Image

11393254-figure-05 (Clopidogrel Tablets Usp 5)

A data table presenting subgroup analysis of clinical outcomes comparing Clopidogrel and placebo. The table lists subgroups based on Heparin/LMWH use, aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use, showing numbers and percentages of events for each treatment group and corresponding hazard ratios with 95% confidence intervals displayed in a forest plot format.*

FDA Label Image

11393254-figure-06 (Clopidogrel Tablets Usp 6)

A line graph comparing the percentage of patients dead before first discharge over 28 days since randomization between two groups: placebo and clopidogrel. The y-axis shows the percentage dead before discharge, and the x-axis shows days since randomization. The graph notes 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the clopidogrel group with a 7% proportional risk reduction (p=0.03) for clopidogrel.*

FDA Label Image

11393254-figure-07 (Clopidogrel Tablets Usp 7)

A Kaplan-Meier curve comparing the percentage of patients experiencing death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph shows event rates for placebo and clopidogrel groups labeled with event counts and percentages, highlighting a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

11393254-figure-08 (Clopidogrel Tablets Usp 8)

A forest plot chart showing subgroups comparing Clopidogrel versus placebo across various factors including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart depicts odds ratios with 99% confidence intervals for each subgroup, summarizing the overall effect size and variability across populations.*

FDA Label Image

11393254-figure-09 (Clopidogrel Tablets Usp 9)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rates (%) over months of follow-up (0 to 36). Two lines compare aspirin and clopidogrel, with event rates increasing over time. The graph includes a p-value of 0.045 indicating statistical comparison.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.